Study in Adults With Severe Chronic Rhinosinusitis With Nasal Polyposis Treated With Dupilumab in France
← catalyst calendarSponsored by Sanofi (industry) · SNY — their whole pipeline →. With Regeneron Pharmaceuticals.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
150estimated
Sites
1
Country
France
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-10-20 | actual | When the study began enrolling |
| Primary completion | 2026-07-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-31 | estimated | The whole study's end, after follow-up |
| First posted | 2024-05-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Rhinosinusitis With Nasal Polyposis
Intervention
- Drug: Dupilumab
Primary outcomes
what the primary-completion date above is the date OFPatient characteristics: Age
measured At baseline (Day 1)
Patient characteristics: Sex
measured At baseline (Day 1)
Patient characteristics: Weight
measured At baseline (Day 1)
Patient characteristics: Height
measured At baseline (Day 1)
Patient characteristics: Type 2 comorbidities
measured At baseline (Day 1)
Patient characteristics: Medical history
measured At baseline (Day 1)
Patient characteristics: Lifestyle habits
measured At baseline (Day 1)
Disease characteristics: CRSwNP duration
measured At baseline (Day 1)
Disease characteristics: Age at diagnosis of CRSwNP
measured At baseline (Day 1)
Disease characteristics: Blood Eosinophils
measured At baseline (Day 1)
Disease characteristics: Total serum IgE
measured At baseline (Day 1)
Disease characteristics: Anatomopathology
measured At baseline (Day 1)
Disease characteristics: Nasal polyps score (NPS) at baseline
measured At baseline (Day 1)
Disease characteristics: Nasal congestion score (NCS) at baseline
measured At baseline (Day 1)
Disease characteristics: Rhinorrhea score (anterior/posterior) at baseline
measured At baseline (Day 1)
Disease characteristics: VAS for CRSwNP symptoms at baseline
measured At baseline (Day 1)
Disease characteristics: smell test score Visual Analog Scale (VAS) at baseline
measured At baseline (Day 1)
Concomitant and prior medications for CRSwNP or other disease: Number of patients with at least one prior or concomitant SCS
measured From baseline up to 24 months.
Concomitant and prior medications for CRSwNP or other disease:Type of prior Systemic Corticosteroids (SCS) per patient
measured From baseline up to 24 months.
Concomitant and prior medications for CRSwNP or other disease: Cumulative dose of SCS
measured From baseline up to 24 months.
Concomitant and prior medications for CRSwNP or other disease: Total number of SCS bursts per patient
measured From baseline up to 24 months.
Concomitant and prior medications for CRSwNP or other disease: Recovery of sense of smell after SCS
measured From baseline up to 24 months.
Concomitant and prior medications for CRSwNP or other disease:Time since the most recent SCS burst before initiation of Dupixent®
measured From baseline up to 24 months.
Concomitant and prior medications for CRSwNP or other disease: Number of prior or respiratory concomitant biotherapies per patient
measured From baseline up to 24 months.
Concomitant and prior medications for CRSwNP or other diseases: Indication
measured From baseline up to 24 months.
Concomitant and prior medications for CRSwNP or other diseases: Reason for stop
measured From baseline up to 24 months.
Dupilumab (Dupixent®) modalities: Dosage
measured From baseline up to 24 months.
Dupilumab (Dupixent®) modalities: Injection modalities
measured From baseline up to 24 months.
Dupilumab (Dupixent®) modalities: Treatment duration
measured From baseline up to 24 months.
Dupilumab (Dupixent®) modalities: Compliance with treatment
measured From baseline up to 24 months.
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed